.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
QuintilesIMS
Chubb
Mallinckrodt
Argus Health
Harvard Business School
Teva
UBS
Moodys
Citi

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,344,011

« Back to Dashboard

Which drugs does patent 8,344,011 protect, and when does it expire?


Patent 8,344,011 protects VIBERZI and is included in one NDA.

This patent has fifty-eight patent family members in thirty-two countries.

Summary for Patent: 8,344,011

Title:Compounds as opioid receptor modulators
Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). ##STR00001## The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Inventor(s): Breslin; Henry J. (Lansdale, PA), Cai; Chaozhong (North Wales, PA), He; Wei (Audubon, PA), Kavash; Robert W. (Glenside, PA)
Assignee: Janssen Pharmaceutica, N.V. (Beerse, BE)
Application Number:12/838,825
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► Subscribe TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► Subscribe TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,344,011

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,741,356Compounds as opioid receptor modulators► Subscribe
8,772,325Compounds as opioid receptor modulators► Subscribe
9,205,076Compounds as opioid receptor modulators► Subscribe
9,700,542Compounds as opioid receptor modulators► Subscribe
8,609,709Compounds as opioid receptor modulators► Subscribe
7,786,158Compounds as opioid receptor modulators► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,344,011

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan200539876► Subscribe
Slovenia2653465► Subscribe
Slovenia2573068► Subscribe
Slovenia2298744► Subscribe
Slovenia1725537► Subscribe
Serbia55122► Subscribe
Serbia54199► Subscribe
Serbia52933► Subscribe
Serbia51995► Subscribe
Portugal2653465► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Harvard Business School
US Department of Justice
Federal Trade Commission
Queensland Health
US Army
Chinese Patent Office
Express Scripts
Johnson and Johnson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot